Remdesivir-Gilead Sciences’ anti-viral drug does not assist in reducing mortality due to Covid-19 or decrease the hospital stay, the World Health Organization's (WHO) Solidarity trial has found.
In response, however, the drug maker released a statement suggesting that the Solidarity trial is inconsistent and has not been subjected to a rigorous review.
From the 2743 recruited for being treated with remdesivir, 301 died. In comparison, the control group that did not receive remdesivir recorded 303 deaths from the 2708 participants.
The study stated that there was no significant difference in the death rate ratio between the ones who received and did not receive remdesivir.
Remdesivir is widely being used in 5 or 10 doses across the world to combat Covid-19.